<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04805385</url>
  </required_header>
  <id_info>
    <org_study_id>CMUH109-REC2-188</org_study_id>
    <nct_id>NCT04805385</nct_id>
  </id_info>
  <brief_title>Effects of Lactobacillus Plantarum PS128 in Patients With Tourette's Syndrome</brief_title>
  <official_title>Effects of Lactobacillus Plantarum PS128 in Patients With Tourette's Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bened Biomedical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>China Medical University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate whether supplementing with PS128 can improve the symptoms and quality of life&#xD;
      related to Tourette's disease in children.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized double-blind healthy control study and the implementation period is&#xD;
      after Institutional Review Board (IRB) approval to December 31, 2022.&#xD;
&#xD;
      Experimental group: 80 subjects who meet the criteria for the admission of Tourette's disease&#xD;
      will be enrolled. They will consume the PS128 or placebo capsules every day, 2 capsules at a&#xD;
      time, for 12 weeks. Healthy control group: 40 subjects of the same age as the experimental&#xD;
      group will be included, without any intervention measures, only collect stool sample once.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Yale Global Tic Severity Scale (YGTSS)</measure>
    <time_frame>From Baseline to 12 Weeks Assessed</time_frame>
    <description>The YGTSS scale refers to Yale Global Tic Severity Scale, and it is a rating tool used to gauge the course of Tourette's syndrome in patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Beck Youth Inventories (BYI-II)</measure>
    <time_frame>From Baseline to 12 Weeks Assessed</time_frame>
    <description>The new Beck Youth Inventories™ Second Edition (BYI-2) uses five self-report inventories to assess symptoms of depression, anxiety, anger, disruptive behavior, and self-concept in children and adolescents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Attention-Deficit/Hyperactivity Disorder Test (ADHDT)</measure>
    <time_frame>From Baseline to 12 Weeks Assessed</time_frame>
    <description>The test yields standard scores, percentile ranks, severity levels, and probability of ADHD.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swanson, Nolan, and Pelham, Version IV (SNAP-IV)</measure>
    <time_frame>From Baseline to 12 Weeks Assessed</time_frame>
    <description>The SNAP-IV is a widely-used rating scale used to screen for Attention Deficit Hyperactivity Disorder.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Child Behavior Checklist (CBCL)</measure>
    <time_frame>From Baseline to 12 Weeks Assessed</time_frame>
    <description>The Child Behavior Checklist (CBCL) is a widely used caregiver report form identifying problem behavior in children. It is widely used in both research and clinical practice with youths.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Autism Behavior Checklist-Taiwan Version (ABCT)</measure>
    <time_frame>From Baseline to 12 Weeks Assessed</time_frame>
    <description>The Autism Behavior Checklist (ABC) is one component of the Autism Screening Instrument for Educational Planning (ASIEP) and is the only one that has been evaluated psychometrically. The ABC is a 57-item behavior rating scale assessing the behaviors and symptoms of autism for children 3 and older.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale for GI symptoms (VAS-GI)</measure>
    <time_frame>From Baseline to 12 Weeks Assessed</time_frame>
    <description>Visual Analogue Scale for GI symptoms, VAS-GI (visual analogue scale, VAS 0-10) was designed to measure the response of symptoms and well-being in patients after taking PS128.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gilles de la Tourette Syndrome-Quality of Life Scale (GTS-QOL)</measure>
    <time_frame>From Baseline to 12 Weeks Assessed</time_frame>
    <description>The Gilles de la Tourette Syndrome-Quality of Life Scale (GTS-QOL) is a self-rated disease-specific questionnaire to assess health-related quality of life of subjects with GTS.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Tourette's Syndrome</condition>
  <arm_group>
    <arm_group_label>PS128</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will consume the PS128 capsules every day, 2 capsules at a time, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will consume the placebo capsules every day, 2 capsules at a time, for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PS128</intervention_name>
    <description>Each PS128 capsule contained &gt;1 × 10^10 colony forming units (CFU) with microcrystalline cellulose and weights 425 ± 25 mg The placebo capsules only contained 425 ± 25 mg microcrystalline cellulose</description>
    <arm_group_label>PS128</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 6-12 years old&#xD;
&#xD;
          -  Tourette's disease is diagnosed&#xD;
&#xD;
          -  Make sure it is not caused by medication or other diseases&#xD;
&#xD;
          -  Cause major interference in social interaction, study or work&#xD;
&#xD;
          -  The healthy control group is not diagnosed with Tourette's disease, and is judged by&#xD;
             PI&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have taken antibiotics within a month or are receiving antibiotic treatment&#xD;
&#xD;
          -  Used probiotic products in powder, capsule or tablet form within two weeks (except&#xD;
             yogurt, yogurt, Yakult and other related foods)&#xD;
&#xD;
          -  Patients who have undergone hepatobiliary gastrointestinal surgery (except for&#xD;
             colorectal polypectomy and appendectomy)&#xD;
&#xD;
          -  Inflammatory bowel disease, such as Crohn's disease or ulcerative colitis&#xD;
&#xD;
          -  Those with a history of cancer&#xD;
&#xD;
          -  Those who are allergic to lactic acid bacteria products&#xD;
&#xD;
          -  Those who are not suitable to participate judged by PI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>12 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>I-Ching Chou, MD</last_name>
    <phone>+886 4 22052121</phone>
    <phone_ext>4641</phone_ext>
    <email>iching@mail.cmu.edu.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404332</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <contact>
      <last_name>I-Ching Chou, MD</last_name>
      <phone>+886 4 22052121</phone>
      <phone_ext>4641</phone_ext>
      <email>iching@mail.cmu.edu.tw</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 17, 2021</study_first_submitted>
  <study_first_submitted_qc>March 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 18, 2021</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tourette Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

